semaglutide for prediabetes Semaglutide, a second-generation GLP-1 receptor agonist, was associated with significantly reduced body weight and other metabolic factors in adults with schizophrenia, prediabetes, and overweight/obesity compared with placebo, research from September Editors Choice Dost Ongur.mp4

While causation has not been definitively established, researchers have noted patterns that warrant further investigation, particularly in patients with underlying risk factors

Protect from direct light exposure and avoid repeated freeze-thaw cycles to maintain complex integrity and ensure consistent experimental results

Due to its special composition, Burgerstein Probase is also excellent as a mineral supplement

Emerging frontiers in GLP-1 therapeutics: A comprehensive evidence base (2025)

Senolytic therapies may be an effective approach for preventing cancer recurrence and therapy resistance

Preliminary human studies associate specific microbial signatures with mood states, and probiotic interventions are under investigation for mood stabilization by reducing systemic inflammation